Form 4: Arcturus Therapeutics Director Moncef Slaoui Receives Annual Stock Option Grant

Arcturus Therapeutics Holdings Inc. director Moncef Slaoui was granted 15,000 stock options with an exercise price of $12.54 as part of his 2025 annual board compensation.

Summary

• Moncef Slaoui, a Director of Arcturus Therapeutics Holdings Inc. (ARCT), was granted 15,000 stock options.
• The stock options have an exercise price of $12.54 per share.
• The transaction date for this grant was June 9, 2025.
• The options will vest monthly over a one-year period from the grant date.
• The expiration date for these options is June 9, 2035.
• This grant represents the 2025 annual compensation for Mr. Slaoui's service on the Board of Directors.

Sentiment

Score: 7

Explanation: The filing reports a standard, expected annual stock option grant to a director, which is a neutral event but positively aligns management incentives with shareholder interests.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a sustained long-term incentive for the director.

Negatives

• No specific negative points identified from this standard compensation filing.

Risks

• No specific risks related to company operations or financial health are disclosed in this Form 4 filing, as it pertains solely to insider stock ownership changes.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook, as its purpose is to report changes in beneficial ownership.

Industry Context

The granting of stock options to board members is a common practice across various industries, particularly in biotechnology and high-growth sectors, to attract and retain talent and align director incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of 15,000 stock options to a director is a typical form of non-cash compensation for board service in the biotechnology industry, comparable to practices at companies like Moderna or BioNTech, where equity incentives are used to align leadership with long-term R&D and commercialization goals.
• The exercise price of $12.54 per share is based on the market price at the time of grant, which is standard for such equity awards.
• The 10-year expiration period and one-year monthly vesting schedule are also common structures for director stock options, providing a sustained incentive.

Related Party Transactions

• Grant of 15,000 stock options to Moncef Slaoui, a Director of Arcturus Therapeutics Holdings Inc., as part of his annual compensation.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, potentially leading to better long-term performance and increased shareholder value if the stock price appreciates.
• Employees: No direct impact on general employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Continued vesting of the granted stock options over the next year, with full vesting expected by June 9, 2026.

Key Dates

Recommendation

Keywords

Arcturus Therapeutics, ARCT, Moncef Slaoui, stock options, director compensation, SEC Form 4, insider transaction, equity grant